Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Sales | 135,057 | 75,334 | 54,799 | 42,325 | 56,086 |
| Cost of Goods | 29,245 | 22,732 | 6,246 | 1,094 | 258 |
| Gross Profit | 105,812 | 52,602 | 48,553 | 41,231 | 55,829 |
| Operating Expenses | 133,509 | 116,370 | 129,233 | 94,950 | 75,925 |
| Operating Income | -27,452 | -63,036 | -80,434 | -53,625 | -19,839 |
| Interest Expense | 5,201 | 5,581 | 3,274 | 0 | 0 |
| Other Income | 422 | 242 | 229 | 73 | 69 |
| Pre-tax Income | -32,231 | -68,375 | -83,479 | -53,552 | -19,770 |
| Net Income Continuous | -32,231 | -68,375 | -83,479 | -53,552 | -19,770 |
| Net Income | $-32,231 | $-68,375 | $-83,479 | $-53,552 | $-19,770 |
| EPS Basic Total Ops | -0.25 | -0.56 | -0.74 | -0.48 | -0.19 |
| EPS Basic Continuous Ops | -0.25 | -0.56 | -0.74 | -0.48 | -0.19 |
| EPS Diluted Total Ops | -0.25 | -0.56 | -0.74 | -0.48 | -0.19 |
| EPS Diluted Continuous Ops | -0.25 | -0.56 | -0.74 | -0.48 | -0.19 |
| EBITDA(a) | $-25,775 | $-59,817 | $-78,091 | $-52,546 | $-18,743 |